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Psoralen + ultraviolet A-treated psoriasis patients are
at increased risk for squamous cell carcinomas and
basal cell carcinomas; however, the incidence and
risk factors associated with second squamous cell
carcinomas and basal cell carcinomas in this popula-
tion are not well quali®ed. Incidence and risk factors
for second squamous cell carcinomas and basal cell
carcinomas were studied in a cohort of 1380 psoralen
+ ultraviolet A-treated psoriasis patients prospec-
tively followed for over 20 y; 264 had a squamous
cell carcinoma and 258 a basal cell carcinoma after
beginning psoralen + ultraviolet A therapy. After a
®rst squamous cell carcinoma, the risk of a second
squamous cell carcinoma was 26% at 1 y, 62% at
5 y, and 75% at 10 y. Risk increased with high psora-
len + ultraviolet A exposure prior to the ®rst squa-
mous cell carcinoma (hazard ratio 3.32, 95%
con®dence interval 1.53, 7.18). Higher rates of post-
®rst squamous cell carcinoma psoralen + ultraviolet
A treatment also were associated with greater risk
(hazard ratio 1.56 for every additional 10 treatments
per year for patients with low pre-®rst squamous cell
carcinoma psoralen + ultraviolet A exposure, 95%
con®dence interval 1.35, 1.81). Patients exposed to
high levels of tar and/or ultraviolet B before a ®rst
squamous cell carcinoma were also at higher risk
(hazard ratio 1.72, 95% con®dence interval 1.14±
2.60). Risk of a second basal cell carcinoma was 21%
at 1 y, 49% at 5 y, and 61% at 10 y. There was some
evidence that high exposure to psoralen + ultraviolet
A before a ®rst basal cell carcinoma was associated
with increased risk of second basal cell carcinoma
(hazard ratio 1.45, 95% con®dence interval 0.97±
2.17). Higher post-®rst tumor psoralen + ultraviolet
A treatment rates also increased risk (hazard ratio
1.24 for every additional 10 treatments per year, 95%
con®dence interval 1.06±1.47). Psoralen + ultraviolet
A-treated psoriasis patients appear to have a greatly
increased incidence of second squamous cell carci-
noma compared with the general population.
Patients who develop a squamous cell carcinoma
after starting psoralen + ultraviolet A therapy should
be closely monitored for a subsequent squamous cell
carcinoma. J Invest Dermatol 118:1038±1043, 2002
S
ince demonstrated in 1974 to be highly effective for
psoriasis (Parrish et al, 1974), orally administered psoralens
and long-wave ultraviolet radiation (UVA) (PUVA) have
been widely used to treat psoriasis.
Non-melanoma skin cancers (NMSC) increasingly
account for morbidity and health-care costs as well as mortality
(Preston and Stern, 1992). An estimated 1.3 million NMSC
[approximately 20% squamous cell carcinomas (SCC) and 80%
basal cell carcinomas (BCC)] will be diagnosed in the United States
in 2001, making them the most common cancers in that country
(Miller and Weinstock, 1994; Alam and Ratner, 2001).
Psoriasis patients not exposed to carcinogenic therapies do not
appear to be at substantially increased risk for SCC or BCC
compared with the general population (Stern et al, 1982a; Alderson
and Clarke, 1983; Hogan et al, 1989; Lindelof et al, 1990);
however, compared with the general population, PUVA-treated
psoriasis patients have an increased risk of cutaneous cancers,
including NMSC, particularly SCC and, to a lesser extent, BCC
(Stern et al, 1979, 1984, 1998; Henseler et al, 1987; Stern and
Lange, 1988; Forman et al, 1989; Bruynzeel et al, 1991; Lindelof et
al, 1991; Chuang et al, 1992; Stern and Laird, 1994).
In addition to PUVA, factors reported to increase risk of NMSC
among PUVA-treated psoriasis patients include lighter skin type
(Forman et al, 1989; Stern and Laird, 1994), tar, and ultraviolet
(UV) B treatments (Henseler et al, 1987; Maier et al, 1996), X-ray
therapy (Henseler et al, 1987), and arsenic therapy (Honigsmann et
al, 1980; Stern et al, 1984; Maier et al, 1996). Methotrexate use was
demonstrated to increase risk of NMSC in one report (Henseler et
al, 1987) but not in an earlier study of the cohort analyzed in this
paper (Stern et al, 1982b, 1984). Ionizing radiation therapy
increased risk of NMSC in the cohort analyzed in this study in
an early (Stern et al, 1979) but not a later analysis (Stern and Laird,
1994). Finally, a recent report found cyclosporine use to be
associated with an increased NMSC incidence in this cohort
(Marcil and Stern, 2001).
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Incidence of second NMSC in the general population has been
studied (Epstein, 1973; Bergstresser and Halprin, 1975; Robinson,
1987; Schreiber et al, 1990; Frankel et al, 1992; Marghoob et al,
1993) and recently reviewed and subject to a meta-analysis (Marcil
and Stern, 2000). Second NMSC among PUVA-treated psoriasis
patients, however, have not been systematically assessed. Utilizing
data from a cohort prospectively studied for more than two
decades, this analysis quanti®es the incidence and risk factors of
second SCC and BCC among PUVA-treated psoriasis patients.
MATERIALS AND METHODS
Study population and follow-up The PUVA Follow-up Study
enrolled 1380 psoriasis patients at 16 centers in the United States in 1975
and 1976. Data for this analysis were collected through July 1, 1999.
During each of 18 follow-up cycles since enrollment, patients were
telephoned and asked about number of PUVA treatments received as
well as about health events, including skin cancer diagnoses. Dates, types,
body locations, and numbers of reported skin tumors were con®rmed by
pathology reports. Patients were asked about: (i) past X-ray and arsenic
therapy at the time of enrollment; (ii) tar, UVB, and methotrexate
therapy at entry and during each follow-up cycle; and (iii) cyclosporine
use during each follow-up cycle. This analysis includes all patients who
had at least 6 mo of follow-up after a ®rst postenrollment BCC or SCC.
De®nitions of variables and outcomes Separate analyses were done
for SCC and BCC. Only prospectively ascertained SCC (not including
SCC in situ or keratoacanthomas) or BCC occurring after ®rst treatment
with PUVA were considered in the analysis. Tumors diagnosed during a
180 d ``wash-out'' period after a ®rst tumor, including multiple tumors
diagnosed on the same day as the index tumor, were not considered
second tumors in this analysis. For incidence as well as hazard ratio
calculations, time at risk was de®ned as beginning 6 mo after diagnosis of
a ®rst SCC or BCC (i.e., after the ``wash-out'' period) and ending with
the diagnosis of a second SCC or BCC, respectively, or with loss to
follow-up. Tumor dates and locations on the body were taken from
pathology reports. Only tumors thought to be new primaries, rather than
suspected recurrences, were counted as second tumors.
Age was the age at development of the ®rst tumor. Skin types were
categorized in two groups, I±II or III±VI. Regions of the United States
where patients initially received treatment were categorized as northern,
middle, or southern, as in prior analyses (Stern et al, 1979). Body
locations of ®rst tumors were categorized as more (head or neck) or less
(rest of body) sun exposed.
The number of PUVA treatments received through the interview
cycle during which the ®rst tumor was diagnosed was categorized as low
(0±159), medium (160±259), or high (260+). Exposure to X-ray therapy
or arsenic therapy re¯ected patient self-reporting. Cyclosporine exposure
was considered positive if a patient had used cyclosporine for at least
three consecutive months. High tar and/or UVB exposure corresponded
to 45 or more months of tar treatments and/or 300 or more UVB
treatments by 1989, provided the ®rst SCC or BCC was diagnosed by
1989. Similarly, high methotrexate exposure re¯ected more than 3 y of
therapy, again provided a ®rst SCC or BCC diagnosis by 1989.
Logistic regression models were initially ®tted using the raw number
of post-®rst tumor PUVA treatments. Preliminary results that showed,
counterintuitively, a protective effect of increasing PUVA treatments
were hypothesized to re¯ect the fact that patients who did not develop
second tumors had more time to receive more PUVA treatments. To
correct for this, the number of post-®rst tumor PUVA treatments was
divided by the number of years of follow-up, yielding a post-®rst tumor
PUVA treatment rate that was used in all subsequent analyses. The rate
was modeled using two variables, allowing simultaneous estimation of
effects of a rate of zero, or an increasing rate of, PUVA treatments after
the ®rst tumor. The reference group for this variable throughout the
analyses is patients with a rate of nearly (but not) zero PUVA treatments
per year.
Statistical analysis For univariate analyses, all variables were
individually entered linearly into Cox proportional hazards models (Cox,
1972; Armitage and Berry, 1994; Collett, 1994). In each analysis, only
variables trending toward signi®cance in univariate analyses (p < 0.15)
were entered into a multivariate model. Backward-stepwise procedures
(Altman, 1991) were used to identify variables signi®cantly related to
second tumor risk in multivariate analyses. Interactions between all
variables in ®nal models were tested for signi®cance using likelihood
ratio tests. Proportional hazards assumptions for each model were tested
using score residuals (Collett, 1994; Stern Reference Manual, 1999).
Kaplan±Meier and predicted survival functions were generated using
standard techniques. All statistical analyses were performed with Stata 6.0
(Stata, College Station, TX).
RESULTS
Baseline and follow-up characteristics Of 1380 PUVA
Follow-up Study patients, 276 had a postenrollment SCC and
265 a postenrollment BCC before July 1, 1999. Of these, 264 with
an SCC and 258 with a BCC had at least 6 mo of follow-up and
were included in this analysis. Characteristics of these cohorts are
shown in Table I. For the SCC cohort, median overall follow-up
time was 2.5 y (minimum 0.5, maximum 22.5, 1080.2 total
person-years of follow-up). For BCC, it was 3.3 y (minimum 0.5,
maximum 21.5, 1326.6 total person-years of follow-up).
Based on Kaplan±Meier estimates (Fig 1), the percentages with a
second SCC at 1, 3, 5, 10, and 15 y were 26.2%, 49.7%, 62.1%,
75.1%, and 90.8%, respectively. For a second BCC the corres-
ponding percentages were 21.1%, 40.8%, 49.2%, 61.4%, and
69.9%, respectively.
Univariate analyses of risk factors associated with second
tumors In univariate analyses for both cohorts (Table II),
PUVA exposure prior to a ®rst tumor was signi®cantly related to
risk of a second tumor of the same type. The rate of post-®rst
tumor PUVA exposure was also associated with second tumor risk
for both cohorts. Among patients who received a minimal (but
nonzero) rate of post-®rst tumor PUVA treatments, risk of a second
SCC or BCC increased linearly with the rate; however, for both
tumor types, risk was, counterintuitively, higher among patients
who received no post-®rst tumor PUVA treatments than those
who received low rates. High tar and/or UVB exposure prior to
the ®rst SCC was signi®cantly related to risk of developing a second
SCC, and there was some evidence of a similar relationship for
BCC. Treatment with methotrexate prior to developing a ®rst
tumor was a signi®cant risk factor for a second SCC.
Multivariate analyses of risk factors associated with second
tumors In multivariate analysis (Table III), high pre-®rst tumor
PUVA exposure remained a signi®cant risk factor in both cohorts.
Patients with high pre-®rst SCC PUVA exposure had a hazard ratio
of 3.32 (95% CI 1.53, 7.18) compared with those with low pre-®rst
SCC PUVA exposure, assuming that both had very low (but
nonzero) post-®rst SCC PUVA treatment rates.
For BCC (Table IV), evidence for an association between pre-
®rst tumor PUVA exposure and risk of a second BCC was of
borderline statistical signi®cance (p = 0.07). Nevertheless, because
this ®nding was biologically plausible, it was kept in the
multivariate model. For second BCC, patients with high pre-®rst
SCC PUVA exposure had a hazard ratio of 1.45 (95% CI 0.97,
2.17) compared with patients with low pre-®rst BCC PUVA
exposure, regardless of the post-®rst BCC PUVA treatment rate for
either patient.
Higher rates of post-®rst tumor PUVA treatments were also
signi®cant risk factors for both cohorts. For the SCC cohort only,
risk associated with post-®rst tumor rates depended on pre-®rst
tumor PUVA exposure (p < 0.01 for the interaction). The
additional risk associated with every 10 treatment rate increase
was highest among patients who had low pre-®rst tumor PUVA
exposure (HR 1.56, 95% CI, 1.35, 1.81) and lowest among patients
with high pre-®rst tumor PUVA exposure (HR 1.12, 95% CI 1.06,
1.18). As in univariate analyses, patients in either cohort who
received no PUVA treatments after a ®rst tumor were at higher risk
than those who received low rates of post-®rst tumor PUVA
treatment. For second SCC, the magnitude of this risk also
depended on the level of pre-®rst tumor PUVA exposure, with
risks highest among patients with low exposure (HR 3.64, 95% CI
1.75, 7.56) and lowest among patients with medium exposure (HR
2.45, 95% CI 1.28, 4.69).
In the BCC cohort, risk associated with post-®rst tumor PUVA
treatment rates was independent of pre-®rst tumor PUVA expos-
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ure. The hazard ratio for every additional 10 treatments per year
after a ®rst BCC was 1.24 (95% CI 1.06, 1.47). Patients with no
post-®rst BCC PUVA treatments had a hazard ratio of 4.18 (95%
CI, 2.54, 6.88) compared with patients with low (but nonzero)
rates of treatment.
A high level of exposure to tar and/or UVB prior to a ®rst tumor
was a risk factor only for second SCC and did not depend on pre-
®rst SCC PUVA exposure (HR 1.72, 95% CI 1.14, 2.60).
Methotrexate was not a signi®cant risk factors for second SCC or
BCC in the multivariate analyses.
Based on the multivariate models, predicted percentages of
patients with various combinations of risk factors developing a
second SCC or BCC over time are shown in Figs 2 and 3. Among
patients with a ®rst SCC, 50% of highest-risk patients (group H in
Fig 2) would be expected to have a second SCC in 0.9 y after the
``wash-out'' period. By comparison, the model predicts that it
would take 14.8 y after the ``wash-out'' period for half of patients
with the lowest-risk pro®le (group A in Fig 2) to have a second
SCC. For patients with a ®rst BCC, the median predicted time to a
second BCC is 2.8 y for highest-risk patients (group F in Fig 3),
whereas even after 20 y of follow-up less than half of the lowest-
risk patients (group A in Fig 3) would be expected to have had a
second BCC.
DISCUSSION
PUVA-treated psoriasis patients appear to have a higher incidence
of second SCC than other populations studied. In this study's
cohort, 26% had a second SCC in the ®rst year of follow-up after
the 6 mo ``wash-out'' period, compared with 9% of patients
enrolled in a clinical trial of b-carotene to prevent skin cancer
(Karagas et al, 1992) and 17% of patients living in south-east
Arizona, a high-risk area (Schreiber et al, 1990). Within 3 y, 47% of
our cohort had had a second SCC, compared with an estimate of
only 18% of patients in a meta-analysis (Marcil and Stern, 2000).
The 5 y incidence of a second SCC in our cohort (62%) was
markedly higher than both the clinical trial (31%) (Karagas et al,
1992) and the Arizona study (» 20%) (Schreiber et al, 1990). Owing
to limited follow-up, no other study has reported a 10 y incidence
of second SCC (75% in our cohort) or a 15 y incidence (91%).
Additionally, as this analysis did not count as positive for second
Table I. Characteristics of psoriasis patients in the PUVA Follow-up Study who developed a SCC or a BCC and had at
least 6 mo of follow-up
Patients with a ®rst SCC
(n = 264)
Patients with a ®rst BCC
(n = 258)
Mean age at ®rst tumor (SD) 60.7 11.9 61.1 (12.5)
Men (%) 198 (75.0) 184 (71.3)
Skin type (%)
1±2 80 (30.3) 82 (31.8)
3±6 157 (59.5) 155 (60.1)
Missing 27 (10.2) 21 (8.1)
Region of residence at time of initial survey (%)
North 139 (52.7) 144 (55.8)
Middle 43 (16.3) 47 (18.2)
South 81 (31.1) 67 (26.0)
First tumor located on head or neck (%) 44 (16.7) 67 (26.0)
Number of PUVA treatments before ®rst tumor (%)
Low (0±159) 91 (34.5) 117 (45.4)
Medium (160±259) 74 (28.0) 61 (23.6)
High (260+) 99 (37.5) 80 (31.0)
Number of PUVA treatments after ®rst tumor
Patients with 0 treatments (%) 145 (54.9) 164 (63.6)
If > 0, median number of treatments (minimum, maximum) 75 (1, 464) 65.5 (1, 485)
History of X-ray therapy for psoriasis at time of entry into study 80 (30.3) 75 (29.1)
History of arsenic therapy for psoriasis at time of entry into study 10 (3.8) 10 (3.9)
History of tar treatment (45+ months) and/or UVB treatments (300+) as of January 1, 1989 84 (31.8) 85 (33.0)
History of methotrexate therapy (3+ years) as of January 1, 1989 81 (30.7) 75 (29.1)
History of cyclosporine therapy (3 or more consecutive months) during follow-up 8 (3.0) 9 (3.5)
Percentage of with a second tumor of same type (95% con®dence interval) at:
1 y 26.2 (21.3, 32.0) 21.1 (16.6, 26.7)
3 y 49.7 (43.5, 56.2) 40.8 (34.8, 47.3)
5 y 62.1 (55.7, 68.7) 49.2 (43.8, 55.9)
10 y 75.1 (68.4, 81.2) 61.4 (54.5, 68.4)
15 y 90.8 (81.2, 96.7) 69.9 (61.0, 78.3)
Figure 1. Kaplan±Meier survival curves for PUVA-treated
psoriasis patients in the PUVA Follow-up Study. The curves show
the percentage of patients who developed either a second SCC after a
®rst postenrollment SCC or a second BCC after a ®rst postenrollment
BCC. After a 6 mo ``wash-out'' period, the 1 y, 3 y, 5 y, 10 y, and 15 y
incidences of a second SCC were 26%, 50%, 62%, 75%, and 91%.
Corresponding incidences for a second BCC were 21%, 41%, 49%, 61%,
and 70%.
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SCC 17 patients whose only subsequent SCC was during the
``wash-out'' period, our estimates may be more conservative than
those of other studies.
In contrast, second BCC incidence during the ®rst year of
follow-up after the ``wash-out'' period (21%) within the ranges of
1 y incidences reported in the clinical trial (17%) (Karagas et al,
1992), the Arizona study (33%) (Schreiber et al, 1990), and a report
on a northern California cohort (20%) (Epstein, 1973). The 3 y
incidence (41%) was close to that reported in the meta-analysis
(44%) (Marcil and Stern, 2000). The 5 y incidence in this cohort
(49%) was similar to the rate among patients in the clinical trial
(41%) (Karagas et al, 1992) and the rate among the Arizona patients
(» 50%) (Schreiber et al, 1990). As for SCC, there are no studies
that compare with the 10 and 15 y second BCC incidences in our
cohortÐ64% and 70% in our cohort. As with the SCC cohort,
conservative estimates of second BCC incidence may have resulted
from the fact that 21 patients whose only subsequent BCC was
diagnosed during the ``wash-out'' period were not considered as
positive for second BCC.
Greater exposure to PUVA before a ®rst tumor was signi®cantly
and strongly related to risk of second SCC (p < 0.01) but only
marginally associated with risk of a second BCC (p = 0.07). These
Table II. Univariate analysis of potential risk factors associated with development of a second SCC or a second BCC in
patients in the PUVA Follow-up Study
Potential risk factor
Patients with a ®rst SCC (n = 276) Patients with a ®rst BCC (n = 265)
Hazard
ratio 95% CI p-value
Hazard
ratio 95% CI p-value
Age at ®rst tumor, for every additional 10 y 1.01 0.89, 1.15 0.86 1.13 0.99, 1.30 0.08
Men, compared with women 1.20 0.84, 1.72 0.31 1.22 0.83, 1.77 0.31
Skin types III±VI, compared with types I±II 0.98 0.70, 1.37 0.90 1.43 0.97, 2.10 0.07
Region of residence, compared with
north
0.70a 0.02a
middle 1.19 0.79, 1.80 0.54 0.32, 0.92
south 1.00 0.71, 1.40 1.12 0.77, 1.63
First tumor not on head or neck 1.16 0.77, 1.74 0.48 1.38 0.91, 2.08 0.13
Pre-®rst tumor PUVA treatment category, compared with
low category (< 160 treatments)
< 0.01b 0.04b
medium (160±259 treatments) 1.37 1.14, 1.65 1.23 1.02, 1.50
high (260+ treatments) 1.88 1.30, 2.72 1.52 1.03, 2.25
Post-®rst tumor PUVA treatment rate < 0.01c < 0.01c
0 2.11 1.52, 2.94 4.31 2.63, 7.10
If > 0, for every additional 10 treatments per year 1.13 1.10, 1.17 1.28 1.09, 1.51
X-ray therapy prior to entering study 1.21 0.87, 1.68 0.26 1.17 0.82, 1.67 0.40
Arsenic therapy prior to entering study 0.87 0.38, 1.96 0.74 0.66 0.27, 1.61 0.36
High tar and/or UVB exposure prior to developing
®rst SCC/BCC
1.85 1.25, 2.74 < 0.01 1.54 0.98, 2.42 0.06
High methotrexate exposure prior to developing ®rst
SCC/BCC
1.56 1.04, 2.40 0.03 1.45 0.91, 2.32 0.12
Cyclosporine use prior to developing ®rst SCC/BCC 1.84 0.68, 4.98 0.23 1.64 0.60, 4.44 0.33
Cyclosporine use after developing ®rst SCC/BCC 2.40 0.88, 6.50 0.09 0.93 0.29, 2.91 0.90
ap-value for region covariate overall.
bp-value for model of pre-®rst tumor PUVA treatment categories, ®tted linearly.
cp-value for model of post-®rst tumor PUVA treatment rate, ®tted using two variables (as explained in text), tested jointly for statistical signi®cance.
Table III. Risk factors associated with a second postenrollment SCC in patients in the PUVA Follow-up Study, from
multivariate analysis
Risk factor Hazard ratio 95% CI p-value
Pre-®rst SCC PUVA exposure category, compared with low
(< 160 treatments), for patients with a PUVA treatment rate
of nearly (but not) zero after the ®rst SCC
< 0.01a
Medium (160±259 treatments) 2.23 1.01, 4.92
High (260+ treatments) 3.32 1.53, 7.18
Post-®rst tumor PUVA treatment rate
0
for patients with low pre-®rst SCC PUVA exposure 3.64 1.75, 7.56
for patients with medium pre-®rst SCC PUVA exposure 2.45 1.28, 4.69
for patients with high pre-®rst SCC PUVA exposure 2.72 1.63, 4.55
If > 0, for every additional 10 treatments per year
for patients with low pre-®rst SCC PUVA exposure 1.56 1.35, 1.81
for patients with medium pre-®rst SCC PUVA exposure 1.14 1.07, 1.22
for patients with high pre-®rst SCC PUVA exposure 1.12 1.06, 1.18
Tar/UVB use prior to developing ®rst SCC 1.72 1.14, 2.60 0.01
aP-value for pre-®rst SCC PUVA treatment category, post-®rst SCC PUVA treatment rate category, and terms for interactions between those two variables, tested jointly.
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®ndings accord with results from ®rst tumor studies in our cohort
and other PUVA-treated psoriasis cohorts, which have found that
PUVA increases SCC risk more than it does BCC risk (Stern and
Lange, 1988; Forman et al, 1989; Bruynzeel et al, 1991; Chuang et
al, 1992; Stern and Laird, 1994; Stern and Lunder, 1998).
For both types of tumors, risk of a second tumor increased with
the yearly rate of post-®rst tumor PUVA treatments. The ®nding in
the SCC cohort that this risk was inversely related to pre-®rst SCC
PUVA exposure suggests that PUVA-associated SCC risk may
begin to plateau once a certain level of total PUVA exposure has
been achieved.
For both SCC and BCC, patients receiving no post-®rst tumor
PUVA treatments at all had a higher risk of second tumors than
those who received a low rate of post-tumor PUVA. This
counterintuitive ®nding is most likely consistent with selection
bias, which may have resulted if PUVA had been discontinued
altogether at the time of the ®rst tumor for patients who were
thought to be (and indeed were) at high risk for subsequent tumors,
based on ®rst tumor size or appearance or the clinical appearance of
the patient's skin. These same concerns about second tumor risk
might also have led to more frequent clinical follow-up for these
patients, increasing the chance of earlier detection (but not
development) of second tumors compared with other patients.
The ®nding that high tar and/or UVB exposure before a ®rst
SCC increased risk of a second SCC supports a prior observation of
this association in ®rst NMSC's among PUVA-treated psoriasis
patients (Henseler et al, 1987). A similar effect was seen when
cumulative high exposure to tar and/or UVB as of 1989 (regardless
of date of ®rst tumor) was entered into logistic regression models. It
is important to note that this analysis cannot distinguish the effects
of topical tar, which is no longer widely used in treating psoriasis,
from those of UVB, which is still widely used. Nevertheless, a
history of extensive treatment with tar and/or UVB prior to a ®rst
SCC should be considered in estimating the risk of further PUVA
and/or UVB treatments.
Table IV. Risk factors associated with a second postenrollment BCC in patients in the PUVA Follow-up Study, from
multivariate analysis
Risk factor Hazard ratio 95% CI p-value
Pre-®rst tumor PUVA treatment category, compared with low category
(< 160 treatments)
0.07a
medium (160±259 treatments) 1.20 0.98, 1.47
high (260+ treatments) 1.45 0.97, 2.17
Post-®rst tumor PUVA treatment rate < 0.01b
0 4.18 2.54, 6.88
If > 0, for every additional 10 treatments per year 1.24 1.06, 1.47
ap-value for model of pre-®rst tumor PUVA treatment categories, ®tted linearly.
bp-value for model of post-®rst tumor PUVA treatment rate, ®tted using two variables (as explained in text), tested jointly for statistical signi®cance.
Figure 2. Percentages of PUVA-treated psoriasis patients
predicted to develop a second postenrollment SCC over a 20 y
follow-up period. According to PUVA treatment category prior to the
®rst SCC, post-®rst SCC PUVA treatment rate, and history of tar/UVB
therapy. Groups A±H are de®ned as follows:
Group
No. of PUVA treatments
before ®rst SCC
Average yearly PUVA
treatment rate after
®rst SCC Prior tar/UVB
A Low (<160) Nearly zero No
B Low 10 No
C Low Zero No
D Low Zero Yes
E High (260+) Nearly zero No
F High 10 No
G High Zero No
H High Zero Yes
Figure 3. Percentages of PUVA-treated psoriasis patients
predicted to develop a second postenrollment BCC over a 20 y
follow-up period. According to PUVA treatment category prior to the
®rst BCC, and post-®rst BCC PUVA treatment rate. Groups A±F are
de®ned as follows:
Group
No. of PUVA treatments
before ®rst BCC
Average yearly PUVA
treatment rate after ®rst BCC
A Low (<160) Nearly zero
B Low 10
C Low Zero
D High (260+) Nearly zero
E High 10
F High Zero
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Lack of an association between cyclosporine and second tumors
in multivariate analysis was somewhat surprising, given that
cyclosporine has been shown to increase NMSC incidence in this
cohort over the long term (Marcil and Stern, 2001) and in
transplant recipients, particularly with regard to SCC (London et al,
1995). The most likely explanation is a lack of power to detect an
effect in this more focused analysis, limited to second tumors
occurring at least 6 mo after a ®rst tumor rather than all tumors
occurring during the entire follow-up experience of patients in the
cohort.
After adjustment for other factors, no signi®cant effect of
methotrexate was seen on risk of second tumors of either type, a
®nding consistent with prior investigations of this cohort (Stern et
al, 1982b, 1984).
In contrast to some other studies of patients in the general
population, our multivariate analyses found no association between
risk of a second NMSC and age (Karagas et al, 1992), male sex
(Epstein, 1973; Karagas et al, 1992), skin type (Robinson, 1987;
Karagas et al, 1992), region of the country where a participant
received treatment (Karagas et al, 1992), and the ®rst tumor's
location on a sun-exposed area of the body (Frankel et al, 1992).
Differences in our ®ndings from those in general populations
studied may re¯ect intrinsic biologic differences in NMSC related
to PUVA and those with other etiologies. Alternatively, differences
could be due to limited power in this study.
This study should allow both treating physicians and psoriasis
patients exposed to various PUVA treatments to estimate better
risks of developing a second tumor. Given the demonstrated high
risk of developing second tumors, PUVA-treated psoriasis patients
who have developed an NMSC would appear to merit at least a
yearly examination for new NMSC. Patients at particularly high-
risk might warrant more frequent examinations. Finally, as second
tumor risk increases with an increasing rate of post-®rst tumor
PUVA treatments, continuation of PUVA treatment after a ®rst
NMSC among patients who have had only modest exposure to
PUVA will require that physicians and patients balance risks of
PUVA, including second tumors (and especially SCC), with the
bene®ts it affords for the management of severe psoriasis.
We thank Beverly Rockhill for providing biostatistical advice. This work was
supported by NIH Contract NO1-AR-4-2214 and NIH Contract N01-AR-
0-2246.
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